

# Collaborative Working Project Executive Summary

## Haematology Capacity and Resource Service Improvement Project

### Project Title:

A Collaborative Working Agreement between Shrewsbury and Telford Hospital NHS Trust and Johnson and Johnson Innovative Medicines UK to identify potential solutions to address the Trust's current and projected Systemic Anti-Cancer Therapy (SACT) delivery capacity challenges.

### Partner Organisations:

Shrewsbury and Telford Hospital NHS Trust, Royal Shrewsbury Hospital, Mytton Oak Road, SY3 8XQ.

Johnson and Johnson Innovative Medicines UK, 50-100 Holmers Farm Way, High Wycombe, Bucks HP12 4EG.

### Project Rationale:

The Trust have identified that there are inefficiencies in the current Haematology service, leading to increased patient waiting times and increased backlogs in patient access. The Trust wants to ensure equity of access to haematology treatments across the Shrewsbury and Telford area, as well as equitable delivery of treatments across its diverse demographic and rural geography

### Project Period:

Nov 2025 – Feb 2026.

### Project Objectives:

The Project will aim to develop recommendations for solutions to manage the current and future increase in demand on the Haematology SACT Service. Solutions will be focussed on increasing capacity, enabling timely treatment delivery, and supporting delivery of NHS treatment targets for the current / future patient population, that could be achieved if project solutions are implemented.

### Patient Specific:

Based on a successful project, patients will have access to care without delay, through access to outpatient services that optimise treatment and clinical care, while reducing waiting time or rescheduled appointments.

**Trust Specific:**

The Project will provide outputs focussed on addressing current and future demand on the Haematology SACT Service and will propose solutions to support consideration of improved workforce planning, updated patient flow pathways and alternative delivery options. The Trust may choose to implement these, or other potential solutions, at its own discretion after completion of the Project.

**Johnson and Johnson company specific:**

Produce an example of a successful collaboration with the NHS which can be used as a case study.

This case study will be utilised with other NHS organisations to develop and scale solutions to similar challenges, allowing the therapeutic landscape to evolve for current and future indications of both haematological and solid tumour therapies.

**Contact Details**

Johnson and Johnson Innovative Medicines UK: Maria Walsh, Business Unit Director  
Oncology

Shrewsbury and Telford Hospital NHS Trust: Dr Emma Litt, Consultant Haematologist